Marshall Wace
ZBIO

Marshall Wace’s Zenas BioPharma ZBIO Stock Holding History

Marshall Wace’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.81M Buy
501,928
+494,828
+6,969% +$11.1M 0.01% 985
2025
Q4 		$258K Buy
+7,100
New +$234K ﹤0.01% 2506

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Marshall Wace's ZBIO Position: Q1 2026 in Review

Marshall Wace increased its Zenas BioPharma (ZBIO) stake by 6,969% in Q1 2026, buying an estimated $11.1M and bringing the position to 501,928 shares worth $9.81M. The position accounts for 0.01% of the portfolio, ranked #985.

Marshall Wace first reported a position in ZBIO in Q4 2025 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Marshall Wace held 501,928 shares of Zenas BioPharma worth $9.81M as of Q1 2026.
  • Marshall Wace bought 494,828 Zenas BioPharma shares in Q1 2026, an estimated $11.1M.
  • Zenas BioPharma made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #985 holding.
  • Marshall Wace first reported a position in Zenas BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.